Results 121 to 130 of about 97,799 (286)

The risk of death according to left ventricular ejection fraction and right ventricular dilatation in 17 321 adults with heart failure from 40 high‐, middle‐ and low‐income countries – A Global Congestive Heart Failure (G‐CHF) study

European Journal of Heart Failure, EarlyView.
Abstract Aims The aim of this study was to describe the prognostic importance of left ventricular ejection fraction (LVEF) versus right ventricular (RV) dilatation and dysfunction in patients with heart failure (HF) from countries of different income levels. Methods and results We enrolled 17 321 participants with HF from 40 countries.
Darryl P. Leong, Philip G. Joseph, Hisham Dokainish, Stefan Störk, John V.V. McMurray, Lisa M. Mielniczuk, Sanjib Kumar Sharma, Andrés Orlandini, Kamilu M. Karaye, Antoni Bayes‐Genis, Tara McCready, Alex Grinvalds, Kumar Balasubramanian, Kelley R. Branch, Kristian Kragholm, Salim Yusuf, on behalf of the G‐CHF Investigators   +16 more
wiley   +1 more source

Natural products targeting regulated cell deaths for adriamycin-induced cardiotoxicity

Cell Death Discovery
Adriamycin (ADR), as an anti-cancer drug in routine clinical application, is utilized to treat various cancers such as ovarian cancer, hematological malignant tumor, and endometrial carcinoma.
Zheng Wang, Yanli Zhu, Yu Yao, Wenyu Zhang, Bo Wang, Jing Wang, Yang Yang, Liwen Liu   +7 more
doaj   +1 more source

Cardiac rhythm devices in heart failure with reduced ejection fraction – role, timing, and optimal use in contemporary practice. European Journal of Heart Failure expert consensus document

European Journal of Heart Failure, EarlyView.
Abstract Guidelines for management of heart failure with reduced ejection fraction (HFrEF) emphasize personalized care, patient engagement, and shared decision‐making. Medications and cardiac rhythm management (CRM) devices are recommended with a high level of evidence. However, there are significant disparities: patients who could benefit from devices
Biykem Bozkurt, Wilfried Mullens, Christophe Leclercq, Andrea M. Russo, Gianluigi Savarese, Michael Böhm, Loreena Hill, Koichiro Kinugawa, Naoki Sato, William T. Abraham, Antoni Bayes‐Genis, Alexandre Mebazaa, Giuseppe M.C. Rosano, Shelley Zieroth, Cecilia Linde, Javed Butler   +15 more
wiley   +1 more source

Endocarditis and Hypertrophic Cardiomyopathy

JACC: Case Reports
Infective endocarditis (IE) is an uncommon but potentially fatal complication in patients affected by hypertrophic cardiomyopathy (HCM). The risk has been described to be significantly higher than in the general population, but the incidence of IE in HCM population remains unknown.
Sebastiano Bertola, Davide Margonato, Alessandra Roccabruna, Martina Belli, Alessandro Malagoli, Martina Setti, Federica Ilardi, Matteo Lisi, Giulia Elena Mandoli, Maria Concetta Pastore, Simona Sperlongano, Marco Matteo Ciccone, Saverio Muscoli, Eustachio Agricola, Giovanni Benfari, Matteo Cameli, Antonello D’Andrea   +16 more
openaire   +1 more source

The use of left ventricular ejection fraction in the diagnosis and management of heart failure. A clinical consensus statement of the Heart Failure Association (HFA) of the ESC, the Heart Failure Society of America (HFSA), and the Japanese Heart Failure Society (JHFS)

European Journal of Heart Failure, EarlyView.
Abstract This clinical consensus statement revisits the role of left ventricular ejection fraction (LVEF) as a measurement of cardiac function, a prognostic marker and a major criterion to classify patients with heart failure, and gives new advice for clinical practice.
Giuseppe M.C. Rosano, John R. Teerlink, Koichiro Kinugawa, Antoni Bayes‐Genis, Ovidiu Chioncel, James Fang, Barry Greenberg, Nasrien E. Ibrahim, Teruhiko Imamura, Takayuki Inomata, Koichiro Kuwahara, Brenda Moura, Anekwe Onwuanyi, Naoki Sato, Gianluigi Savarese, Yasuhiko Sakata, Nancy Sweitzer, Jane Wilcox, Kazuhiro Yamamoto, Marco Metra, Andrew J.S. Coats   +20 more
wiley   +1 more source

Clinical and plasma proteomic characterization of heart failure with supranormal left ventricular ejection fraction: An emerging entity of heart failure

European Journal of Heart Failure, EarlyView.
Heart failure (HF) with supranormal ejection fraction (HFsnEF) is an unnoticed but emerging entity in HF. This study showed that HFsnEF carries a similarly increased cardiovascular risk as HF with reduced ejection fraction (HFrEF) and distinct structural and proteomic characteristics from HFrEF, warranting a further comprehensive understanding and ...
Yasuhiko Sakata, Kotaro Nochioka, Satoshi Yasuda, Koichi Ishida, Takashi Shiroto, Jun Takahashi, Shintaro Kasahara, Ruri Abe, Shinsuke Yamanaka, Takahide Fujihashi, Hideka Hayashi, Shintaro Kato, Katsunori Horii, Kanako Teramoto, Tsutomu Tomita, Satoshi Miyata, Koichiro Sugimura, Iwao Waga, Masao Nagasaki, Hiroaki Shimokawa   +19 more
wiley   +1 more source

Cancer therapy‐related cardiotoxicity is associated with distinct alterations of the myocardial lipidome

European Journal of Heart Failure, EarlyView.
Lipidome changes in anthracycline‐induced cardiotoxicity (AIC). Aims Anthracyclines are key components of various chemotherapy regimens, but their clinical utility is limited by severe cardiotoxic side effects. Previous studies have suggested that anthracycline‐induced cardiotoxicity (AIC) may be driven by alterations in myocardial lipid metabolism ...
Vera M. Braun, Anna Foryst‐Ludwig, Ulf Landmesser, István Baczkó, Hendrik Milting, Ulrich Kintscher, Niklas Beyhoff   +6 more
wiley   +1 more source

Patient and Disease-Specific Induced Pluripotent Stem Cells for Discovery of Personalized Cardiovascular Drugs and Therapeutics. [PDF]

, 2020
Human induced pluripotent stem cells (iPSCs) have emerged as an effective platform for regenerative therapy, disease modeling, and drug discovery.
Chandy, Mark, Paik, David T, Wu, Joseph C   +2 more
core  

Prediction and prognostic role of left ventricular systolic dysfunction in family screening for dilated cardiomyopathy and non‐dilated left ventricular cardiomyopathy

European Journal of Heart Failure, EarlyView.
Aims The prognostic significance of detecting left ventricular (LV) systolic dysfunction during family screening programmes (FSPs) in relatives of probands affected by dilated (DCM) and non‐dilated left ventricular (NDLVC) cardiomyopathies remain unclear.
Eva Del Mestre, Alessia Paldino, Carola Pio Loco Detto Gava, Ilaria Gandin, Marta Gigli, Davide Stolfo, Martina Setti, Giovanni Maria Severini, Beatrice Spedicati, Stefania Lenarduzzi, Giorgia Girotto, Alessandro Folgheraiter, Jacopo Giulio Rizzi, Renata Korcova, Luisa Mestroni, Marco Merlo, Matteo Dal Ferro, Gianfranco Sinagra   +17 more
wiley   +1 more source

Mitochondrial targets in ischaemic heart disease and heart failure, and their potential for a more efficient clinical translation. A scientific statement of the ESC Working Group on Cellular Biology of the Heart and the ESC Working Group on Myocardial Function

European Journal of Heart Failure, EarlyView.
Improving clinical translation of mitoprotective therapies. 31P MRI, phosphorus‐31 magnetic resonance imaging; hiPSC‐CM, human‐induced pluripotent stem cell‐derived cardiomyocyte; IHD, ischaemic heart disease. Abstract Acute myocardial infarction (MI) remains a major cause of death and disability worldwide.
Melanie Paillard, Mahmoud Abdellatif, Ioanna Andreadou, Christian Bär, Luc Bertrand, Bianca J.J.M. Brundel, Gemma Chiva‐Blanch, Sean M. Davidson, Dana Dawson, Fabio Di Lisa, Paul Evans, Zoltan Giricz, Derek J. Hausenloy, Petra Kleinbongard, Frank Lezoualc'h, Elisa Liehn, Christoph Maack, Ange Maguy, Elizabeth Murphy, Cinzia Perrino, Maurizio Pesce, Peter P. Rainer, Katrin Streckfuss‐Bömeke, Matthias Thielmann, Rong Tian, Carlo G. Tocchetti, Jolanda Van Der Velden, Sophie Van Linthout, Serena Zacchigna, Thomas Krieg   +29 more
wiley   +1 more source